July 7 (Reuters) - Eisai Co Ltd and Biogen Inc's Leqembi emerged as the first Alzheimer's treatment to win the U.S. Food and Drug Administration's standard approval on Thursday, a milestone in drug development for a disease that has seen multiple failures in the past. The following is a list of companies that are currently developing treatments that aim to modify the memory-robbing disease: Company Drug or Stage of Mechanism Therapy development & indication Eli Lilly donanemab Designed to and Co Late-stage trial target toxic for early protein plaque Alzheimer’s in the brain known as beta-amyloid and remove brain plaques to slow cognitive decline BioVie Inc NE3107 An oral small Late-stage trial molecule that for mild to aims to inhibit moderate neuroinflammati Alzheimer’s on and insulin resistance AB Science masitinib An oral SA Late-stage study tyrosine kinase for inhibitor that mild-to-moderate targets immune Alzheimer’s cells responsible for neuroinflammati on Annovis buntanetap An Bio Inc Mid-to-late-stage orally-administ trial for moderate ered small Alzheimer's molecule inhibitor of several neurotoxic proteins Cognition CT1812 Oral drug Therapeuti Mid-stage trial designed to cs Inc for bind to a mild-to-moderate specific Alzheimer’s receptor in brain cells, which mediates the attachment of beta-amyloid Coya COYA 301 Designed to Therapeuti Mid-stage trial inhibit cs Inc for molecules mild-to-moderate responsible for Alzheimer’s neuroinflammati on and improve cognitive function Actinogen xanamem Blocks Medical Mid-stage trial production of a Limited for mild-moderate hormone linked Alzheimer's to stress called cortisol inside brain cells and is associated with cognitive impairment AC Immune ACI-24.060 Early- An SA -to-mid stage antibody-based trial for immunotherapy Alzheimer’s vaccine designed to target beta amyloid plaques Biogen Inc BIIB080 An antisense Mid-stage trial oligonucleotide for early-stage therapy Alzheimer’s directed against "tau" proteins Longeveron lomecel-B A cell therapy Inc Mid-stage trial designed to for mild stimulate Alzheimer’s neuroregenerati on and prevent disease progression (Reporting by Pratik Jain and Mariam Sunny in Bengaluru; Editing by Maju Samuel)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
219.7 USD | +0.37% | +1.66% | -15.09% |
02:28pm | Redburn Atlantic Adjusts Price Target on Biogen to $235 From $275, Keeps Neutral Rating | MT |
05-07 | FDA Sets June 10 Advisory Panel Meeting on Eli Lilly Alzheimer's Drug | DJ |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
6,610 JPY | +0.23% | +1.66% | 12.24B | ||
2,706 PTS | -1.45% | -1.34% | - | ||
775 USD | -0.36% | -0.23% | 700B | ||
219.7 USD | +0.37% | +1.66% | 31.87B | ||
8.03 USD | -0.86% | -7.38% | 118M | ||
4.82 USD | -9.91% | -21.11% | 58.91M | ||
2.35 USD | -1.26% | -6.00% | 224M | ||
2.03 EUR | +1.50% | +6.95% | 110M | ||
2 USD | +4.17% | +2.56% | 76.88M | ||
1.66 USD | -1.19% | -4.60% | 12.09M | ||
0.4853 USD | -0.45% | -1.56% | 26.76M | ||
0.032 AUD | 0.00% | -15.79% | 49.24M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.09% | 31.87B | |
-2.35% | 89.33B | |
+4.08% | 41.19B | |
+53.68% | 24.52B | |
-15.13% | 15.68B | |
-8.63% | 12.34B | |
-40.39% | 12.23B | |
+6.22% | 8.83B | |
-6.43% | 8.28B | |
-6.45% | 7.52B |
- Stock Market
- Equities
- BIIB Stock
- News Biogen Inc.
- Companies in Alzheimer's race after US nod for Eisai/Biogen drug